## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($475.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Johnson Financial Group Inc. Sells 1,831 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T112251 | Bullish | Relevance: 99%
- Johnson Financial Group Inc. significantly reduced its stake in HCA Healthcare, Inc. by selling 1,831 shares, retaining only 230 shares worth approximately $88,000. Despite this sell-off, HCA Healthcare reported strong quarterly earnings, beating analyst estimates, which led to analysts raising their price targets and maintaining a "Moderate Buy" consensus. The article also highlights other institutional and insider trading activities, including increased holdings by some institutions and sales by executive VPs.

**2. HCA Healthcare (NYSE:HCA) Cut to "Hold" at Zacks Research**
- Source: MarketBeat | 20251130T123232 | Neutral | Relevance: 99%
- Zacks Research downgraded HCA Healthcare (NYSE:HCA) from a "strong-buy" to a "hold" rating, despite the company beating Q3 earnings and revenue estimates and setting strong FY2025 guidance. HCA Healthcare currently trades near its 52-week high with a market cap of approximately $117 billion, and analysts maintain a consensus "Moderate Buy" rating with an average price target of $474.53. The article also details recent insider stock sales and institutional trading activity, noting a significant increase in institutional holdings.

**3. J.W. Cole Advisors Inc. Sells 1,025 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T115111 | Somewhat-Bullish | Relevance: 99%
- J.W. Cole Advisors Inc. reduced its stake in HCA Healthcare by selling 1,025 shares, while other major institutional investors significantly increased their holdings. The article also details recent insider selling by two executive VPs, HCA Healthcare's strong financial performance beating analyst expectations, and a declared quarterly dividend. Analyst ratings for HCA Healthcare remain largely positive with a "Moderate Buy" consensus.

**4. HCA Healthcare, Inc. $HCA Shares Acquired by Dixon Mitchell Investment Counsel Inc.**
- Source: MarketBeat | 20251201T095435 | Bullish | Relevance: 99%
- Dixon Mitchell Investment Counsel Inc. significantly increased its stake in HCA Healthcare, making the stock its 29th largest holding. The article details HCA's strong Q3 earnings, positive FY2025 guidance, and a "Moderate Buy" consensus from analysts, alongside notable institutional investor activity and insider stock sales.

**5. Capital Fund Management S.A. Lowers Stock Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251130T084449 | Neutral | Relevance: 99%
- Capital Fund Management S.A. significantly reduced its stake in HCA Healthcare by 35.5% in Q2 2025, selling 31,878 shares and ending with 57,983 shares valued at approximately $22.2 million. This reduction occurred despite HCA Healthcare posting stronger-than-expected Q3 results and receiving multiple analyst price-target increases, leading to a "Moderate Buy" consensus rating. Additionally, company insiders, including EVPs Michael S. Cuffe and Michael R. McAlevey, also sold substantial portions of their HCA stock holdings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.8x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.8 |
| Current P/E | 18.1 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.1% to -1.7% (-6.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.85), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.74% (CS: 42) | Neutral |
| RSI_14 | 64.7 | Neutral |
| MACD Histogram | 0.85 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.103x | Above |
| vs SMA200 | 1.298x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $500.31
- **Stop Loss:** $475.61 (4.9% risk)
- **Target:** $525.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $20,012.40
- **Portfolio %:** 20.01%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*